{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T21:06:10Z","timestamp":1753736770366},"reference-count":76,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.clindermatol.2011.09.018","type":"journal-article","created":{"date-parts":[[2012,10,13]],"date-time":"2012-10-13T07:42:01Z","timestamp":1350114121000},"page":"657-661","source":"Crossref","is-referenced-by-count":8,"title":["Advances in systemic antifungal therapy"],"prefix":"10.1016","volume":"30","author":[{"given":"David A.","family":"Stevens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2011.09.018_bb0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/514704","article-title":"Lipid formulations of amphotericin B: clinical efficacy and toxicities","volume":"27","author":"Wong-Beringer","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0010","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.mycmed.2005.06.005","article-title":"Dupont B. Lipid formulations of amphotericin B: Where are we today?","volume":"15","author":"Antoniadou","year":"2005","journal-title":"J Mycol Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0015","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/clind\/15.6.1003","article-title":"Evolving role of flucytosine in immunocompromised patients\u2014new insights into safety, pharmacokinetics, and antifungal therapy","volume":"15","author":"Francis","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0020","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJM198708063170602","article-title":"Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks","volume":"317","author":"Dismukes","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0025","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1592\/phco.19.8.603.31529","article-title":"Itraconazole in cyclodextrin solution","volume":"19","author":"Stevens","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0030","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/archinte.1997.00440370097010","article-title":"Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria","volume":"157","author":"Stevens","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0035","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM200003163421102","article-title":"A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis","volume":"342","author":"Stevens","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0040","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-133-9-200011070-00009","article-title":"A comparison of oral fluconazole or itraconazole for progressive, nonmeningeal coccidioidomycosis","volume":"133","author":"Galgiani","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0924-8579(95)00010-6","article-title":"Itraconazole for the treatment of histoplasmosis and blastomycosis","volume":"5","author":"Mangino","year":"1995","journal-title":"Int J Antimicrob Ag"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0050","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0002-9343(93)90280-3","article-title":"Treatment of sporotrichosis with itraconazole","volume":"95","author":"Sharkey-Mathis","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0055","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1439-0507.1988.tb04419.x","article-title":"Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea pedis and tinea manuum","volume":"31","author":"Van Hecke","year":"1988","journal-title":"Mycoses"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0060","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1046\/j.1365-2141.1999.01465.x","article-title":"A randomised controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies","volume":"105","author":"Morgenstern","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0065","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1086\/313654","article-title":"A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients","volume":"30","author":"Nucci","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0070","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/515129","article-title":"Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial","volume":"28","author":"Menichetti","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0075","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7326\/0003-4819-135-6-200109180-00010","article-title":"Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial","volume":"135","author":"Boogaerts","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0080","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1086\/514028","article-title":"A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis","volume":"176","author":"Wilcox","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-9343(97)00307-0","article-title":"Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV\/AIDS patients","volume":"104","author":"Graybill","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0090","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0924-8579(93)90009-T","article-title":"Fluconazole (Diflucan): a review","volume":"3","author":"Zervos","year":"1993","journal-title":"Int J Antimicrob Ag"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0095","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0100","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/374850","article-title":"A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects","volume":"36","author":"Rex","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJM199201093260202","article-title":"Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis","volume":"326","author":"Saag","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","article-title":"Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome","volume":"337","author":"Van der Horst","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0115","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJM199203193261203","article-title":"A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome","volume":"326","author":"Powderly","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0120","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/infdis\/170.1.238","article-title":"High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection","volume":"170","author":"Haubrich","year":"1994","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.clindermatol.2011.09.018_bb0125","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/clinids\/14.Supplement_1.S68","article-title":"A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group","volume":"14","author":"Diaz","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0002-9343(99)80371-4","article-title":"Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis","volume":"98","author":"Catanzaro","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0135","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0140","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation\u2014a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0145","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-120-11-199406010-00003","article-title":"Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program","volume":"120","author":"Menichetti","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0150","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7326\/0003-4819-118-7-199304010-00003","article-title":"Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial","volume":"118","author":"Winston","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0155","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial","volume":"96","author":"Marr","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0160","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1056\/NEJM199110313251803","article-title":"Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole","volume":"325","author":"Wingard","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0165","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.37.9.1847","article-title":"Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients","volume":"37","author":"Wingard","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0170","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.1993.tb00184.x","article-title":"Successful treatment of sporotrichosis with oral fluconazole: a report of three cases","volume":"128","author":"Castro","year":"1993","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.clindermatol.2011.09.018_bb0175","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1470-9465.2004.00838.x","article-title":"Voriconazole\u2014a new therapeutic agent with an extended spectrum of antifungal activity","volume":"10","author":"Donnelly","year":"2004","journal-title":"Clinical Microbiol Infect"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0180","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.2165\/00003495-200262180-00010","article-title":"Voriconazole in the treatment of invasive aspergillosis","volume":"62","author":"Muijsers","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0185","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0190","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0195","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less-common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0200","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0205","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1086\/375080","volume":"36","author":"Deresinski","year":"2003","journal-title":"Caspofungin. Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0210","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0065-3233(01)56011-8","article-title":"Glucan synthase inhibitors as antifungal agents","volume":"56","author":"Kurtz","year":"2001","journal-title":"Advances In Protein Chemistry"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0215","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/jac\/dkf045","article-title":"Echinocandins: a new class of antifungal","volume":"49","author":"Denning","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0220","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMct060052","article-title":"Echinocandins for candidemia in adults without neutropenia","volume":"355","author":"Bennett","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0225","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1592\/phco.27.3.369","article-title":"The echinocandins","volume":"27","author":"Cappelletty","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0230","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0235","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01191-9","article-title":"A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis","volume":"113","author":"Villanueva","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0240","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00126334-200210010-00009","article-title":"Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole","volume":"31","author":"Kartsonis","year":"2002","journal-title":"J Acq Immune Defic Syndrome Hum Retrovirol"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0245","first-page":"377","article-title":"SCH56592","volume":"1","author":"Espinel-Ingroff","year":"1997","journal-title":"Current Opin Anti-infective Drugs"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0250","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1086\/523576","article-title":"Reviews of anti-infective agents: Posaconazole: a broad-spectrum triazole antifungal agent","volume":"45","author":"Nagappan","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0255","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","article-title":"Oral bioavailability of posaconazole in fasted healthy subjects\u2014comparison between three regimens and basis for clinical dosage recommendations","volume":"44","author":"Ezzet","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0260","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0265","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1086\/504328","article-title":"Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0270","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft- versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0275","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0280","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.07-0114","article-title":"Posaconazole therapy for chronic refractory coccidioidomycosis","volume":"132","author":"Stevens","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0285","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1310\/hct0802-86","article-title":"Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection","volume":"8","author":"Vazquez","year":"2007","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0290","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1086\/503425","article-title":"Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0295","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1128\/AAC.00398-07","article-title":"Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing","volume":"51","author":"Hope","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0300","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1517\/14656566.8.8.1155","article-title":"The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety","volume":"8","author":"Wiederhold","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0305","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0310","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0315","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s10096-005-0024-8","article-title":"International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia","volume":"24","author":"Ostrosky-Zeichner","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0320","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1365-2036.2005.02427.x","article-title":"A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis","volume":"21","author":"de Wet","year":"2005","journal-title":"Aliment Pharmacol Therapeut"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0325","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1086\/423377","article-title":"A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients","volume":"39","author":"de Wet","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0330","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1128\/AAC.49.4.1331-1336.2005","article-title":"Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant","volume":"49","author":"Hiemenz","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0335","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.bmt.1705398","article-title":"A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation","volume":"38","author":"Sirohi","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0340","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0345","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jinf.2006.03.003","article-title":"Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis","volume":"53","author":"Denning","year":"2006","journal-title":"J Infection"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0350","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/AAC.50.2.632-638.2006","article-title":"Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections","volume":"50","author":"Benjamin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0355","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1086\/505204","article-title":"Anidulafungin: a novel echinocandin","volume":"43","author":"Vazquez","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0360","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1439-0507.2007.01378.x","article-title":"Anidulafungin\u2014state of affairs from a clinical perspective","volume":"50","author":"Vehreschild","year":"2007","journal-title":"Mycoses"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0365","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/AAC.48.6.2021-2024.2004","article-title":"Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia","volume":"48","author":"Krause","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0370","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0375","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/10408410903213393","article-title":"Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing, and antimicrobial susceptibility","volume":"35","author":"van Asbeck","year":"2009","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.clindermatol.2011.09.018_bb0380","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1128\/CMR.18.1.163-194.2005","article-title":"Combination treatment of invasive fungal infections","volume":"18","author":"Mukherjee","year":"2005","journal-title":"Clin Microbiol Rev"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X11002975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X11002975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T19:18:26Z","timestamp":1594754306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X11002975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0738081X11002975"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2011.09.018","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}